🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)

Found 9 matching trials

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

PHASE3

This is a Phase IIIb, multinational, multicenter, randomized, open-label st...

Status

Completed

Location

Centro de Investigaciones Médicas y Desarrollo LC S.R.L

Start Date

2022-07-05

Trial ID

NCT05415215

Treatments Being Tested

Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)Pertuzumab IV Trastuzumab IV Trastuzumab Emtansine Investigator's Choice of Chemotherapy Surgery Radiotherapy

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

PHASE2

This is a Phase II, randomized, multicentre, multinational, open-label, cro...

Status

Completed

Location

Rocky Mountain Cancer Center - Lakewood (West)

Start Date

2018-12-19

Trial ID

NCT03674112

Treatments Being Tested

Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)Pertuzumab IV Trastuzumab IV

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

PHASE2

This is a multicenter, open-label, single-arm, one-stage, phase II study to...

Status

Active Not Recruiting

Location

UMHAT Sveti Ivan Rilski EAD Department of Medical Oncology

Start Date

2021-08-05

Trial ID

NCT04733118

Treatments Being Tested

Trastuzumab and Pertuzumab (FDC SC) and T-DM1

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

PHASE3

This study will evaluate the pharmacokinetics, efficacy, and safety of the ...

Status

Completed

Location

Peking University People's Hospital

Start Date

2020-02-05

Trial ID

NCT04024462

Treatments Being Tested

Pertuzumab IV Trastuzumab IV Pertuzumab and Trastuzumab FDC SC Doxorubicin Cyclophosphamide Docetaxel Surgery Post-Operative Radiotherapy Hormone Therapy

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

PHASE3

This Phase III, randomized, two-arm, open-label, multicenter study will eva...

Status

Active Not Recruiting

Location

Arizona Clinical Research Center, Inc

Start Date

2022-07-18

Trial ID

NCT05296798

Treatments Being Tested

Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocrine Therapy of Investigator's Choice

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

PHASE2

The study consists of a screening period of 28 days, a treatment period. Lo...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2025-12-15

Trial ID

NCT07245797

Treatments Being Tested

fixed-dose combination of pertuzumab and trastuzumab as subcutaneousformulation q3w and nab-paclitaxel in 3-week cycle for total 6 cycles with inavolisib (6 cycles) or without inavolisib.

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

PHASE1

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study i...

Status

Recruiting

Location

City of Hope

Start Date

2021-06-22

Trial ID

NCT04802759

Treatments Being Tested

Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

PHASE2

Evaluation of the potential incremental efficacy and safety of inavolisib i...

Status

Recruiting

Location

KEM Kliniken Essen-Mitte

Start Date

2023-01-02

Trial ID

NCT05306041

Treatments Being Tested

Inavolisib PHESGO Endocrine therapy

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

N/A

This single arm, multicenter study provides the pertuzumab and trastuzumab ...

Status

Approved For Marketing

Location

Beverly Hills Cancer Center

Start Date

TBD

Trial ID

NCT04395508

Treatments Being Tested

Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)

Previous Next